Earnings summaries and quarterly performance for Inhibrx Biosciences.
Executive leadership at Inhibrx Biosciences.
Board of directors at Inhibrx Biosciences.
Research analysts covering Inhibrx Biosciences.
Recent press releases and 8-K filings for INBX.
Inhibrx Biosciences Reports Third Quarter 2025 Financial Results and Positive Ozekibart Trial Data
INBX
Earnings
New Projects/Investments
- Inhibrx Biosciences reported a net loss of $35.3 million, or $(2.28) per share, for the third quarter of 2025, an improvement from a net loss of $43.9 million, or $(2.84) per share, in the prior year period.
- As of September 30, 2025, the company held cash and cash equivalents of $153.1 million.
- The company announced positive topline results from its registrational trial of ozekibart (INBRX-109) in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival.
- Inhibrx plans to submit a biologics license application for ozekibart to the U.S. Food and Drug Administration in the second quarter of 2026.
Nov 14, 2025, 11:00 AM
Inhibrx Biosciences Reports Q3 2025 Financial Results and Positive Ozekibart Trial Data
INBX
Earnings
New Projects/Investments
- Inhibrx Biosciences, Inc. reported a net loss of $35.3 million, or $(2.28) per share, for the third quarter of 2025, compared to a net loss of $43.9 million in the third quarter of 2024.
- As of September 30, 2025, the company's cash and cash equivalents totaled $153.1 million.
- The company announced positive topline results from its registrational trial of ozekibart (INBRX-109) in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival.
- Inhibrx plans to submit a biologics license application for ozekibart to the U.S. Food and Drug Administration in the second quarter of 2026.
Nov 13, 2025, 11:00 PM
Inhibrx Reports Positive OzekiVART Trial Results and Market Opportunities
INBX
New Projects/Investments
M&A
Product Launch
- Inhibrx announced positive top-line results from its registrational trial of OzekiVART in unresectable or metastatic chondrosarcoma, demonstrating a median Progression-Free Survival (PFS) of 5.52 months compared to 2.66 months for placebo, with a hazard ratio of 0.479 (p-value <0.0001).
- The company plans to file a Biologics License Application (BLA) for OzekiVART in chondrosarcoma in the second quarter of 2026.
- Interim results for OzekiVART in combination therapies showed a 23% overall confirmed response rate and 92% disease control rate in evaluable colorectal cancer patients, and a 64% overall response rate and 92% disease control rate in evaluable Ewing sarcoma patients.
- The estimated combined market potential for chondrosarcoma, late-line colorectal cancer, and Ewing sarcoma is greater than $2.5 billion, with individual global peak revenue estimates exceeding $500 million for chondrosarcoma and Ewing sarcoma, and over $1.5 billion for late-line colorectal cancer in the U.S..
- Inhibrx intends to transact the OzekiVART program with a third party to maximize shareholder value and is actively engaged in discussions.
Oct 23, 2025, 8:30 PM
Inhibrx Reports Positive Top-Line Results for Ozekibart in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma
INBX
Product Launch
New Projects/Investments
- Inhibrx reported positive top-line results from its registrational ChonDRAgon trial for ozekibart in unresectable or metastatic chondrosarcoma, demonstrating a median progression-free survival (PFS) of 5.52 months versus 2.66 months for placebo, with a hazard ratio of 0.479 (p-value < 0.0001). The company plans to file a Biologics License Application (BLA) in Q2 2026.
- In expansion cohorts, ozekibart in combination with FOLFIRI achieved a 23% overall confirmed response rate and a 92% disease control rate in heavily pretreated colorectal cancer patients.
- For relapsed or refractory Ewing sarcoma, ozekibart combined with irinotecan and temozolomide showed a 64% overall response rate and a 92% disease control rate in evaluable patients.
- The estimated global peak revenue for ozekibart could exceed $500 million each for chondrosarcoma and Ewing sarcoma, and potentially exceed $1.5 billion in late-line colorectal cancer in the U.S. alone, leading to a combined market potential of greater than $2.5 billion across these indications.
- Inhibrx intends to transact on the ozekibart program with a third party to maximize shareholder value.
Oct 23, 2025, 8:30 PM
Inhibrx Announces Positive OzekiVART Registrational Trial Results and Strategic Plans
INBX
Product Launch
New Projects/Investments
M&A
- Inhibrx reported positive top-line results from its registrational trial (Chondragon) of OzekiVART in unresectable or metastatic chondrosarcoma, demonstrating a median progression-free survival (PFS) of 5.52 months compared to 2.66 months for placebo, representing a 52% reduction in the risk of progression or death (p-value < 0.0001). The company plans to file a Biologics License Application (BLA) in Q2 2026.
- In expansion cohorts, OzekiVART showed a 23% overall confirmed response rate and 92% disease control rate in heavily pretreated colorectal cancer (CRC) patients when combined with FOLFIRI. For relapsed or refractory Ewing sarcoma, in combination with irinotecan and temozolomide, it achieved a 64% overall response rate and 92% disease control rate.
- The estimated global peak revenue for OzekiVART could exceed $500 million for chondrosarcoma and $500 million for Ewing sarcoma, while the late-line U.S. market opportunity for CRC could exceed $1.5 billion, totaling a combined market potential of greater than $2.5 billion across these indications.
- Inhibrx aims to maximize shareholder value by transacting on the OzekiVART program with a third party, focusing on tax efficiency and dilution sensitivity, and is actively engaged in discussions.
Oct 23, 2025, 8:30 PM
Inhibrix Reports Positive Registrational Trial Results for Ozekibart in Chondrosarcoma and Provides Updates on Other Indications
INBX
Product Launch
New Projects/Investments
M&A
- Inhibrix reported positive top-line results from its registrational trial of ozekibart in unresectable or metastatic chondrosarcoma, demonstrating a median progression-free survival (PFS) of 5.52 months compared to 2.66 months for placebo, and a 52% reduction in the risk of progression or death (P < 0.0001).
- Based on these compelling results, Inhibrix plans to file a Biologics License Application (BLA) in 2026.
- Encouraging updates were also provided for expansion cohorts of ozekibart in colorectal cancer (23% overall confirmed response rate, 92% disease control rate) and Ewing sarcoma (64% overall response rate, 92% disease control rate).
- Inhibrix estimates the combined market potential for chondrosarcoma, late-line colorectal cancer, and Ewing sarcoma to be greater than $2.5 billion, with global peak revenue for chondrosarcoma and Ewing sarcoma each potentially exceeding $500 million, and the U.S. late-line colorectal cancer market exceeding $1.5 billion.
- The company's goal is to transact on the ozekibart program by partnering with a third party to bring value to shareholders.
Oct 23, 2025, 8:30 PM
Inhibrx Biosciences to Present Topline Results for Ozekibart in Chondrosarcoma
INBX
New Projects/Investments
- Inhibrx Biosciences will host a webcast presentation on October 23, 2025, at 1:30 p.m. PT, to provide topline results from its registrational ChonDRAgon study of ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma.
- The company will also provide updates on ongoing expansion trials investigating ozekibart in late-line colorectal cancer and refractory Ewing sarcoma.
- Ozekibart (INBRX-109) has received FDA Fast Track designation (January 2021) and Orphan Drug designation (November 2021) for chondrosarcoma.
Oct 22, 2025, 8:01 PM
Inhibrx Biosciences Reports Q2 2025 Financial Results and Upcoming Clinical Milestones
INBX
Earnings
New Projects/Investments
M&A
- Inhibrx Biosciences reported a net loss of $28.7 million, or $1.85 per share, for the second quarter of 2025, a significant decline from a net income of $1.9 billion in the second quarter of 2024, primarily due to a $2.0 billion gain from the INBRX-101 transaction recorded in the prior year.
- As of June 30, 2025, the company held $186.6 million in cash and cash equivalents.
- Research and development expenses decreased substantially to $22.3 million in Q2 2025 from $67.6 million in Q2 2024, and general and administrative expenses fell to $6.4 million from $93.4 million, largely due to non-recurring expenses and activities related to the INBRX-101 program and transaction in 2024.
- The company anticipates key clinical trial data readouts, with results from the ozekibart (INBRX-109) Phase 2 trial expected by late October 2025 and initial Phase 2 data for INBRX-106 during the fourth quarter of 2025.
Aug 13, 2025, 8:05 PM
Inhibrx Biosciences Announces Leadership Changes & Updates
INBX
Management Change
M&A
Executive Compensation
- David J. Matly is promoted to President effective April 1, 2025, with an increased base salary of $601,670, 50,000 stock options vesting over four years, and notable contributions to the $2.2B asset sale of INBRX-101 to Sanofi .
- Dr. Brendan Eckelman, co-founder and former CSO, departs to launch a new biotech company, with his resignation triggering accelerated vesting of 50,000 stock options and an extended exercise period through October 1, 2026 .
- Dr. Carlos Bais is appointed as Chief Scientific Officer .
Apr 1, 2025, 8:05 PM
Inhibrx Biosciences Reports Q4 and Fiscal Year 2024 Results
INBX
Debt Issuance
M&A
- Inhibrx Biosciences reported its Q4 and fiscal year 2024 financial results following the divestiture of the INBRX-101 program and a subsequent spin-off, while advancing two clinical programs with anticipated data readouts within the next 12 months.
- The company bolstered liquidity by reporting $152.6 million in cash as of December 31, 2024, and receiving $100 million from a loan agreement with Oxford Finance—raising cash to $230.5 million by February 2025.
- Q4 performance improved with a reduced net loss of $47.9 million (from $93.6 million in Q4 2023) and a turnaround to a fiscal year net income of $1.7 billion, reflecting the impact of the spin-off transaction.
Mar 17, 2025, 8:05 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more